Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | President | November 19, 2022 | November 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date November 19, 2022 · Filed November 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,234 |
Ending reported balance
After 2022-11-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-11-19 · Exercise / conversion · Acquired 6,250 · Balance 63,081 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2022-11-21 · Sale · Disposed 1,847 · Balance 61,234 F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-21 · Exercise / conversion · Disposed 6,250 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The restricted stock units vest in four equal annual installments beginning November 19, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: The restricted stock units vest in four equal annual installments beginning November 19, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2022 Filed Nov 22, 2022 21:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058391 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning November 19, 2019. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning November 19, 2019. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,847 | $15.07 | $27,834.29 |
DisclosureSEC source: 0001209191-22-058391 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,234 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 19, 2022 Filed Nov 22, 2022 21:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-058391 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 15, 2022 Filed Oct 19, 2022 01:22 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054027 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2022 Filed Oct 19, 2022 01:22 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,326 | $15.81 | $20,964.06 |
DisclosureSEC source: 0001209191-22-054027 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,831 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2022 Filed Oct 19, 2022 01:22 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-054027 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 02, 2022 Filed May 4, 2022 00:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,865 | $18.18 | $52,090.86 |
DisclosureSEC source: 0001209191-22-026940 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,188 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.385, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026940 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,616 Underlying: Common Stock · 9,616 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-026940 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 144,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023739 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,695 Underlying: Common Stock · 144,695 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F4 · derivative.exercise_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 36,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023739 · doc4.xml · derivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,174 Underlying: Common Stock · 36,174 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 124,138 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0001209191-22-023739 · doc4.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,138 Underlying: Common Stock · 124,138 shares Expires 2032-04-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 4,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013275 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,758 Underlying: Common Stock · 4,919 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,501 | $23.80 | $35,723.80 |
DisclosureSEC source: 0001209191-22-013275 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,437 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013275 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002749 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,889 Underlying: Common Stock · 5,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,937 | $23.05 | $44,647.85 |
DisclosureSEC source: 0001209191-22-002749 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,019 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-002749 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,803 | $19.01 | $53,285.03 |
DisclosureSEC source: 0001209191-21-066570 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,512 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066570 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 11/19/2019. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 11/19/2019. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-066570 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 21:31 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,338 | $17.41 | $23,294.58 |
DisclosureSEC source: 0001209191-21-060958 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,065 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 21:31 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060958 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,969 Underlying: Common Stock · 2,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 21:31 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060958 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 22:53 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 4,230 | $20.33 | $85,995.90 |
DisclosureSEC source: 0001209191-21-029357 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,434 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:53 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029357 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,232 Underlying: Common Stock · 9,615 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:53 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029357 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:52 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 19,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014561 · doc4.xml · derivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,677 Underlying: Common Stock · 19,677 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:52 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 72,463 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001209191-21-014561 · doc4.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,463 Underlying: Common Stock · 72,463 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2022. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,875 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0001209191-21-008660 · doc4.xml · derivative · entry 5 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 Underlying: Common Stock · 11,875 shares Expires 2028-10-15 F5 · kind: On October 15, 2018, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 11,875 shares. F5 · derivative.exercise_date: On October 15, 2018, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 11,875 shares. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantEmployee Stock Option (Right to Buy) · Derivative | 21,875 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-21-008660 · doc4.xml · derivative · entry 4 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 21,875 shares Expires 2027-09-07 F4 · kind: On September 7, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 21,875 shares. F4 · derivative.exercise_date: On September 7, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 21,875 shares. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $29.59 | $0.00 |
DisclosureSEC source: 0001209191-21-008660 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2027-08-03 F3 · kind: On August 3, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 15,625 shares. F3 · derivative.exercise_date: On August 3, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 15,625 shares. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 8,429 | $50.61 | $426,591.69 |
DisclosureSEC source: 0001209191-21-008660 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,049 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 19,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008660 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,478 F1 · kind: On April 29, 2019, the reporting person was granted Restricted Stock Units (RSU's) that vest upon the Issuer's satisfaction of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the RSU's as to the number of shares reported in column 4 of row 1 above. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001209191-21-003678 · doc4.xml · derivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,562 Underlying: Common Stock · 700 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on November 19, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 700 | $55.01 | $38,507.00 |
DisclosureSEC source: 0001209191-21-003678 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,247 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 700 | $18.12 | $12,684.00 |
DisclosureSEC source: 0001209191-21-003678 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,488 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · derivative · entry 13 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,262 Underlying: Common Stock · 3,488 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on November 19, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,864 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · derivative · entry 12 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,761 Underlying: Common Stock · 12,864 shares Expires 2028-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,381 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · derivative · entry 11 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 13,381 shares Expires 2027-09-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 29,733 | $55.22 | $1,641,832.47 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · nonDerivative · entry 8 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,247 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2020. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.77 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,488 | $18.12 | $63,202.56 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · nonDerivative · entry 7 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 12,864 | $21.28 | $273,745.92 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · nonDerivative · entry 6 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 13,381 | $35.80 | $479,039.80 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · nonDerivative · entry 5 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 61,619 | $55.12 | $3,396,186.64 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · nonDerivative · entry 4 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,247 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2020. Read SEC document |
| January 07, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 61,619 | $35.80 | $2,205,960.20 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · nonDerivative · entry 3 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,619 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · derivative · entry 10 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,631 Underlying: Common Stock · 61,619 shares Expires 2027-09-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · derivative · entry 9 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,333 Underlying: Common Stock · 5,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,725 | $53.34 | $92,011.50 |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · nonDerivative · entry 2 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,247 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-002831 · doc4.xml · nonDerivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.